The AANEM Board of Directors has endorsed the
International Consensus Guidance for the Management of Myasthenia Gravis, which was recently published in
Neurology, the official journal of the American Academy of Neurology.
This endorsement is a support of the research and findings, and followed the recommendation and approval of the AANEM Professional Practice Committee, and a subsequent review by the AANEM Board of Directors.
This consensus guidance statement was developed by a task force of the Myasthenia Gravis Foundation of America (MGFA) to provide guidance to clinicians who treat patients with myasthenia gravis (MG) and to help MG patients and their families make informed decisions about their treatment. Consensus of expert opinions is used to develop such guidance statements when available studies do not provide strong information about the treatment of a condition. Using the Rand-UCLA Appropriate Method of formal consensus, the MGFA task force panel of 15 physicians from 9 countries developed guidance statements for 7 specific treatment areas, including symptomatic and immunosuppressive therapy, management of MG crisis, thymectomy and management of MG during pregnancy. The Executive Summary and full report of the Guidance Statements are available to the public as Open Access papers and may be accessed on the AANEM website under the
Practice/Guidelines and quality section at
this link.